In this video, Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, presents long-term results of a Phase II study evaluating crenolanib, a potent FLT3 inhibitor, in patients with new diagnosed FLT3-mutated acute myeloid leukemia (AML). In combination with 7+3 induction and consolidation, crenolanib demonstrates high response rates in this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.